应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
DCOY Decoy Therapeutics Inc
交易中 10-07 09:37:26 EDT
1.53
-0.02
-1.29%
最高
1.55
最低
1.53
成交量
1.36万
今开
1.55
昨收
1.55
日振幅
1.29%
总市值
100.24万
流通市值
89.72万
总股本
65.52万
成交额
2.09万
换手率
2.31%
流通股本
58.64万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Decoy Therapeutics宣布达成385万美元权证诱导交易,按纳斯达克规则市价定价
美股速递 · 09-23
Decoy Therapeutics宣布达成385万美元权证诱导交易,按纳斯达克规则市价定价
Decoy Therapeutics提名全球生物制药高管Patricia Gauthier参选董事会董事
美股速递 · 06-03
Decoy Therapeutics提名全球生物制药高管Patricia Gauthier参选董事会董事
Decoy Therapeutics任命麻省理工学院化学教授Brad Pentelute为科学顾问委员会主席
美股速递 · 05-26
Decoy Therapeutics任命麻省理工学院化学教授Brad Pentelute为科学顾问委员会主席
Decoy Therapeutics将出席虚拟投资者收市钟声活动 展望2026年业务前景
美股速递 · 04-06
Decoy Therapeutics将出席虚拟投资者收市钟声活动 展望2026年业务前景
加载更多
公司概况
公司名称:
Decoy Therapeutics Inc
所属市场:
NASDAQ
上市日期:
--
主营业务:
Decoy Therapeutics Inc.是一家于2014年2月26日在特拉华州注册成立的生物技术公司,并且其业务主要发生在马萨诸塞州的波士顿。该公司是一家临床阶段的生物制药公司,专注于为癌症患者开发创新治疗选择。其产品组合包括 seclidemstat,这一主要候选药物目前正在MD安德森癌症中心进行1/2 阶段临床研究,旨在针对骨髓增生异常综合症 (MDS) 和慢性髓单核白血病 (CMML) 等血液系统癌症,特别是为治疗选择有限的患者开发。此外,公司还在推进SP-3164,这是一种口服小分子蛋白降解剂,目前处于新药研究阶段 (IND)。
发行价格:
--
{"stockData":{"symbol":"DCOY","market":"US","secType":"STK","nameCN":"Decoy Therapeutics Inc","latestPrice":1.53,"timestamp":1791380174338,"preClose":1.55,"halted":0,"volume":13560,"delay":0,"changeRate":-0.012903225806451623,"floatShares":586415,"shares":655185,"eps":-40.396286,"marketStatus":"交易中","change":-0.02,"latestTime":"10-07 09:37:26 EDT","open":1.55,"high":1.55,"low":1.53,"amount":20900.521584000002,"amplitude":0.012903,"askPrice":1.54,"askSize":52,"bidPrice":1.52,"bidSize":2,"shortable":3,"etf":0,"ttmEps":-40.396286,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1791403200000},"marketStatusCode":2,"adr":0,"listingDate":1422507600000,"exchange":"NASDAQ","adjPreClose":1.55,"preHourTrading":{"tag":"盘前","latestPrice":1.53,"preClose":1.55,"latestTime":"09:26 EDT","volume":5007,"amount":7631.0390187,"timestamp":1791379569721,"change":-0.02,"changeRate":-0.012903,"amplitude":0.051613},"postHourTrading":{"tag":"盘后","latestPrice":1.56,"preClose":1.55,"latestTime":"19:47 EDT","volume":5929,"amount":9311.7859,"timestamp":1791330448197,"change":0.01,"changeRate":0.006452,"amplitude":0.032258},"volumeRatio":3.672969},"requestUrl":"/m/hq/s/DCOY","defaultTab":"news","newsList":[{"id":"1136687011","title":"Decoy Therapeutics宣布达成385万美元权证诱导交易,按纳斯达克规则市价定价","url":"https://stock-news.laohu8.com/highlight/detail?id=1136687011","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136687011?lang=zh_cn&edition=full","pubTime":"2026-09-23 00:52","pubTimestamp":1790095931,"startTime":"0","endTime":"0","summary":"Decoy Therapeutics, Inc.今日正式对外披露,公司已敲定一项权证诱导交易方案。该交易预计将带来总计385万美元的总收益,且定价方式严格遵循纳斯达克相关规定,选择在市场价位直接执行。通过这一精心筹划的金融安排,Decoy Therapeutics得以在现行市况下引入新一轮资金注入,为后续研发管线推进及运营扩张提供更为充裕的财务支撑。Decoy Therapeutics方面表示,本次交易所得款项将用于一般公司用途,涵盖但不限于在研项目的持续推进以及日常运营开支的补充。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DCOY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110138438","title":"Decoy Therapeutics提名全球生物制药高管Patricia Gauthier参选董事会董事","url":"https://stock-news.laohu8.com/highlight/detail?id=1110138438","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1110138438?lang=zh_cn&edition=full","pubTime":"2026-06-03 20:03","pubTimestamp":1780488220,"startTime":"0","endTime":"0","summary":"Decoy Therapeutics Inc已提名全球生物制药领域的高管Patricia Gauthier参选公司董事会董事。这一提名旨在利用Gauthier在生物制药行业的丰富经验,为董事会的战略决策注入新的专业力量。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DCOY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157548363","title":"Decoy Therapeutics任命麻省理工学院化学教授Brad Pentelute为科学顾问委员会主席","url":"https://stock-news.laohu8.com/highlight/detail?id=1157548363","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157548363?lang=zh_cn&edition=full","pubTime":"2026-05-26 20:15","pubTimestamp":1779797728,"startTime":"0","endTime":"0","summary":"Decoy Therapeutics Inc宣布,已任命麻省理工学院化学系教授Brad Pentelute为其科学顾问委员会主席。这一任命旨在加强公司的科学战略与研发能力。Pentelute教授在化学生物学与蛋白质工程领域的深厚专长,将为Decoy Therapeutics在创新疗法开发方面提供关键指导。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DCOY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182247272","title":"Decoy Therapeutics将出席虚拟投资者收市钟声活动 展望2026年业务前景","url":"https://stock-news.laohu8.com/highlight/detail?id=1182247272","media":"美股速递","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182247272?lang=zh_cn&edition=full","pubTime":"2026-04-06 21:16","pubTimestamp":1775481376,"startTime":"0","endTime":"0","summary":"生物制药企业Decoy Therapeutics Inc(股票代码:DCOY)宣布将参与虚拟投资者收市钟声特别活动。本次线上会议将重点展示公司截至2026年的战略规划与业务发展蓝图,管理层将就研发管线进展、商业化布局及长期增长驱动因素进行深度解读。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DCOY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.decoytx.com","stockEarnings":[{"period":"1week","weight":-0.2723},{"period":"1month","weight":-0.4238},{"period":"3month","weight":-0.7304},{"period":"6month","weight":-0.7417},{"period":"1year","weight":-0.9671},{"period":"ytd","weight":-0.8009}],"compareEarnings":[{"period":"1week","weight":0.0195},{"period":"1month","weight":0.0116},{"period":"3month","weight":0.0452},{"period":"6month","weight":0.1459},{"period":"1year","weight":0.16},{"period":"ytd","weight":0.1425}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Decoy Therapeutics Inc.是一家于2014年2月26日在特拉华州注册成立的生物技术公司,并且其业务主要发生在马萨诸塞州的波士顿。该公司是一家临床阶段的生物制药公司,专注于为癌症患者开发创新治疗选择。其产品组合包括 seclidemstat,这一主要候选药物目前正在MD安德森癌症中心进行1/2 阶段临床研究,旨在针对骨髓增生异常综合症 (MDS) 和慢性髓单核白血病 (CMML) 等血液系统癌症,特别是为治疗选择有限的患者开发。此外,公司还在推进SP-3164,这是一种口服小分子蛋白降解剂,目前处于新药研究阶段 (IND)。","yearOnYearQuotes":[{"month":1,"riseRate":0.454545,"avgChangeRate":0.032258},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.05363},{"month":3,"riseRate":0.416667,"avgChangeRate":-0.015981},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.073653},{"month":5,"riseRate":0.583333,"avgChangeRate":0.034905},{"month":6,"riseRate":0.5,"avgChangeRate":-0.059304},{"month":7,"riseRate":0.25,"avgChangeRate":-0.160563},{"month":8,"riseRate":0.25,"avgChangeRate":-0.124152},{"month":9,"riseRate":0.083333,"avgChangeRate":-0.145356},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.135394},{"month":11,"riseRate":0.363636,"avgChangeRate":-0.062226},{"month":12,"riseRate":0.272727,"avgChangeRate":-0.07199}],"exchange":"NASDAQ","name":"Decoy Therapeutics Inc","nameEN":"Decoy Therapeutics Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Decoy Therapeutics Inc(DCOY)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Decoy Therapeutics Inc(DCOY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Decoy Therapeutics Inc,DCOY,Decoy Therapeutics Inc股票,Decoy Therapeutics Inc股票老虎,Decoy Therapeutics Inc股票老虎国际,Decoy Therapeutics Inc行情,Decoy Therapeutics Inc股票行情,Decoy Therapeutics Inc股价,Decoy Therapeutics Inc股市,Decoy Therapeutics Inc股票价格,Decoy Therapeutics Inc股票交易,Decoy Therapeutics Inc股票购买,Decoy Therapeutics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Decoy Therapeutics Inc(DCOY)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Decoy Therapeutics Inc(DCOY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}